Treating status migrainosus in the emergency setting: what is the best strategy?

References

• Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2163–2196.
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Scher AI, Stewart WF, et al. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia. 2003;23(7):519–527.
   PubMed Web of Science ®Google Scholar
• Leonardi M, Steiner TJ, Scher AT, et al. The global burden of migraine: measuring disability in headache disorders with WHO’s classification of functioning, disability and health (ICF). J Headache Pain. 2005;6(6):429–440.
   PubMedGoogle Scholar
• Fishman P, Black L. Indirect costs of migraine in a managed care population. Cephalalgia. 1999;19(1):50–57.
   PubMed Web of Science ®Google Scholar
• Gerth WC, Carides GW, Dasbach EJ, et al. The multinational impact of migraine symptoms on healthcare utilisation and work loss. PharmacoEconomics. 2001;19(2):197–206.
   PubMed Web of Science ®Google Scholar
• Gyure T, Csepany E, Hajnal B, et al. The comprehensive headache-related quality of life questionnaire shows significant improvement after withdrawal treatment in medication overuse headache: a pilot study. Ideggyogy Sz. 2014;67(5–6):169–176.
   PubMedGoogle Scholar
• Headache classification committee of the International Headache Society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
   PubMed Web of Science ®Google Scholar
• Becker WJ, Kryscio RJ. Treatment of migraine: a headache for the emergency department. Neurology. 2007;69(22):2034–2035.
   PubMed Web of Science ®Google Scholar
• Schulman E. Refractory migraine - a review. Headache. 2013;53(4):599–613.
   PubMed Web of Science ®Google Scholar
• Jones JM. Refractory migraine in a “just world”. Headache. 2015;55(1):183–185.
   PubMed Web of Science ®Google Scholar
• Burch RC, Loder S, Loder E, et al. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache. 2015;55(1):21–34.
   PubMed Web of Science ®Google Scholar
• Long BJ, Koyfman A. Benign headache management in the emergency department. J Emerg Med. 2018;54:458–468.
   PubMedGoogle Scholar
• Vinson DR. Treatment patterns of isolated benign headache in US emergency departments. Ann Emerg Med. 2002;39(3):215–222.
   PubMed Web of Science ®Google Scholar
• Minen MT, Tanev K, Friedman BW. Evaluation and treatment of migraine in the emergency department: a review. Headache. 2014;54(7):1131–1145.
   PubMed Web of Science ®Google Scholar
• Friedman BW, Greenwald P, Bania TC, et al. Randomized trial of IV dexamethasone for acute migraine in the emergency department. Neurology. 2007;69(22):2038–2044.
   PubMed Web of Science ®Google Scholar
• Beltramone M, Donnet A. Status migrainosus and migraine aura status in a French tertiary-care center: an 11-year retrospective analysis. Cephalalgia. 2014;34(8):633–637.
   PubMed Web of Science ®Google Scholar
• Insinga RP, Ng-Mak DS, Hanson ME. Costs associated with outpatient, emergency room and inpatient care for migraine in the USA. Cephalalgia. 2011;31(15):1570–1575.
   PubMed Web of Science ®Google Scholar
• Marcus DA. Treatment of status migrainosus. Expert Opin Pharmacother. 2001;2(4):549–555.
   PubMedGoogle Scholar
• Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache. 1995;35(7):387–396.
   PubMed Web of Science ®Google Scholar
• Rozen TD. Emergency department and inpatient management of status migrainosus and intractable headache. Continuum. 2015;21(4 Headache):1004–1017.
   PubMedGoogle Scholar
• Jones CW, Gaughan JP, McLean SA. Epidemiology of intravenous fluid use for headache treatment: findings from the national hospital ambulatory medical care survey. Am J Emerg Med. 2017;35(5):778–781.
   PubMed Web of Science ®Google Scholar
• Balbin JE, Nerenberg R, Baratloo A, et al. Intravenous fluids for migraine: a post hoc analysis of clinical trial data. Am J Emerg Med. 2016;34(4):713–716.
   PubMed Web of Science ®Google Scholar
• Kopjas TL. Migraine treatment with dexamethasone. Headache. 1967;7(2):77–78.
   PubMedGoogle Scholar
• Lukacs M, Tajti J, Fulop F, et al. Migraine, neurogenic inflammation, drug development - pharmacochemical aspects. Curr Med Chem. 2017;24(33):3649–3665.
   PubMed Web of Science ®Google Scholar
• Tajti J, Szok D, Nagy-Grocz G, et al. Kynurenines and PACAP in migraine: medicinal chemistry and pathogenetic aspects. Curr Med Chem. 2017;24(13):1332–1349.
   PubMed Web of Science ®Google Scholar
• Tajti J, Szok D, Majlath Z, et al. Migraine and neuropeptides. Neuropeptides. 2015;52:19–30.
   PubMed Web of Science ®Google Scholar
• Tajti J, Tuka B, Botz B, et al. Role of pituitary adenylate cyclase-activating polypeptide in nociception and migraine. CNS Neurol Disord Drug Targets. 2015;14(4):540–553.
   PubMed Web of Science ®Google Scholar
• Tajti J, Csati A, Vecsei L. Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors. Expert Opin Drug Metab Toxicol. 2014;10(11):1509–1520.
   PubMed Web of Science ®Google Scholar
• Vecsei L, Tuka B, Tajti J. Role of PACAP in migraine headaches. Brain. 2014;137(Pt 3):650–651.
   PubMedGoogle Scholar
• Tajti J, Pardutz A, Vamos E, et al. Migraine is a neuronal disease. J Neural Transm. 2011;118(4):511–524.
   PubMed Web of Science ®Google Scholar
• Tajti J, Szok D, Pardutz A, et al. Where does a migraine attack originate? In the brainstem. J Neural Transm. 2012;119(5):557–568.
   PubMed Web of Science ®Google Scholar
• Woldeamanuel YW, Rapoport AM, Cowan RP. What is the evidence for the use of corticosteroids in migraine? Curr Pain Headache Rep. 2014;18(12):464.
   PubMed Web of Science ®Google Scholar
• Woldeamanuel YW, Rapoport AM, Cowan RP. The place of corticosteroids in migraine attack management: a 65-year systematic review with pooled analysis and critical appraisal. Cephalalgia. 2015;35(11):996–1024.
   PubMed Web of Science ®Google Scholar
• Czock D, Keller F, Rasche FM, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61–98.
   PubMed Web of Science ®Google Scholar
• Orr SL, Friedman BW, Christie S, et al. Management of adults with acute migraine in the emergency department: the American headache society evidence assessment of parenteral pharmacotherapies. Headache. 2016;56(6):911–940.
   PubMed Web of Science ®Google Scholar
• Ducharme J. Canadian association of emergency physicians guidelines for the acute management of migraine headache. J Emerg Med. 1999;17(1):137–144.
   PubMed Web of Science ®Google Scholar
• Shahrami A, Assarzadegan F, Hatamabadi HR, et al. Comparison of therapeutic effects of magnesium sulfate vs. Dexamethasone/metoclopramide on alleviating acute migraine headache. J Emerg Med. 2015;48(1):69–76.
   PubMed Web of Science ®Google Scholar
• Pryse-Phillips WE, Dodick DW, Edmeads JG, et al. Guidelines for the diagnosis and management of migraine in clinical practice. Canadian headache society. CMAJ: Can Med Assoc J. 1997;156(9):1273–1287.
   PubMed Web of Science ®Google Scholar
• Colman I, Friedman BW, Brown MD, et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ. 2008;336(7657):1359–1361.
   PubMed Web of Science ®Google Scholar
• Giuliano C, Smalligan RD, Mitchon G, et al. Role of dexamethasone in the prevention of migraine recurrence in the acute care setting: a review. Postgrad Med. 2012;124(3):110–115.
   PubMed Web of Science ®Google Scholar
• Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol. 2013;75:365–391.
   PubMed Web of Science ®Google Scholar
• Pietrobon D, Moskowitz MA. Chaos and commotion in the wake of cortical spreading depression and spreading depolarizations. Nat Rev Neurosci. 2014;15(6):379–393.
   PubMed Web of Science ®Google Scholar
• von Luckner A, Riederer F. Magnesium in migraine prophylaxis-is there an evidence-based rationale? A systematic review. Headache. 2018;58(2):199–209.
   PubMed Web of Science ®Google Scholar
• Gertsch E, Loharuka S, Wolter-Warmerdam K, et al. Intravenous magnesium as acute treatment for headaches: a pediatric case series. J Emerg Med. 2014;46(2):308–312.
   PubMed Web of Science ®Google Scholar
• Demirkaya S, Vural O, Dora B, et al. Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. Headache. 2001;41(2):171–177.
   PubMed Web of Science ®Google Scholar
• Choi H, Parmar N. The use of intravenous magnesium sulphate for acute migraine: meta-analysis of randomized controlled trials. Eur J Emerg Med. 2014;21(1):2–9.
   PubMed Web of Science ®Google Scholar
• Robertson CE, Black DF, Swanson JW. Management of migraine headache in the emergency department. Semin Neurol. 2010;30(2):201–211.
   PubMed Web of Science ®Google Scholar
• Calabresi P, Galletti F, Rossi C, et al. Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends Pharmacol Sci. 2007;28(4):188–195.
   PubMed Web of Science ®Google Scholar
• Vecsei L, Majlath Z, Szok D, et al. Drug safety and tolerability in prophylactic migraine treatment. Expert Opin Drug Saf. 2015;14(5):667–681.
   PubMed Web of Science ®Google Scholar
• Hoffmann J, Akerman S, Goadsby PJ. Efficacy and mechanism of anticonvulsant drugs in migraine. Expert Rev Clin Pharmacol. 2014;7(2):191–201.
   PubMed Web of Science ®Google Scholar
• Ayata C, Jin H, Kudo C, et al. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006;59(4):652–661.
   PubMed Web of Science ®Google Scholar
• Bakhshayesh B, Seyed Saadat SM, Rezania K, et al. A randomized open-label study of sodium valproate vs sumatriptan and metoclopramide for prolonged migraine headache. Am J Emerg Med. 2013;31(3):540–544.
   PubMed Web of Science ®Google Scholar
• Deutsch SI, Burket JA, Rosse RB. Valproate-induced hyperammonemic encephalopathy and normal liver functions: possible synergism with topiramate. Clin Neuropharmacol. 2009;32(6):350–352.
   PubMed Web of Science ®Google Scholar
• Nagy F. [Prophylactic migraine treatment with topiramate]. Ideggyogy Sz. 2010;63(7–8):227–230.
   PubMedGoogle Scholar
• Farooq MU, Majid A, Pysh JJ, et al. Role of intravenous levetiracetam in status migrainosus. J Headache Pain. 2007;8(2):143–144.
   PubMedGoogle Scholar
• Tomic MA, Pecikoza UB, Micov AM, et al. The effects of levetiracetam, sumatriptan, and caffeine in a rat model of trigeminal pain: interactions in 2-component combinations. Anesth Analg. 2015;120(6):1385–1393.
   PubMed Web of Science ®Google Scholar
• Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3–20.
   PubMed Web of Science ®Google Scholar
• Tajti J, Majlath Z, Szok D, et al. Drug safety in acute migraine treatment. Expert Opin Drug Saf. 2015;14(6):891–909.
   PubMed Web of Science ®Google Scholar
• Taggart E, Doran S, Kokotillo A, et al. Ketorolac in the treatment of acute migraine: a systematic review. Headache. 2013;53(2):277–287.
   PubMed Web of Science ®Google Scholar
• Friedman BW, Mulvey L, Esses D, et al. Metoclopramide for acute migraine: a dose-finding randomized clinical trial. Ann Emerg Med. 2011;57(5):475–482. e471.
   PubMed Web of Science ®Google Scholar
• Humphrey PP, Feniuk W, Perren MJ, et al. The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia. 1989;9(Suppl 9):23–33.
   PubMedGoogle Scholar
• Tepper SJ. Orally inhaled dihydroergotamine: a review. Headache. 2013;53(Suppl 2):43–53.
   PubMedGoogle Scholar
• Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003;43(2):144–166.
   PubMed Web of Science ®Google Scholar
• Berard A, Kori S. Dihydroergotamine (DHE) use during gestation and the risk of adverse pregnancy outcomes. Headache. 2012;52(7):1085–1093.
   PubMed Web of Science ®Google Scholar
• Viana M, Afridi S. Migraine with prolonged aura: phenotype and treatment. Naunyn Schmiedebergs Arch Pharmacol. 2018;391(1):1–7.
   PubMed Web of Science ®Google Scholar
• Afridi SK, Giffin NJ, Kaube H, et al. A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology. 2013;80(7):642–647.
   PubMed Web of Science ®Google Scholar
• Cuadrado ML, Aledo-Serrano A, Lopez-Ruiz P, et al. Greater occipital nerve block for the acute treatment of prolonged or persistent migraine aura. Cephalalgia. 2017;37(8):812–818.
   PubMed Web of Science ®Google Scholar
• Thissen S, Vos IG, Schreuder TH, et al. Persistent migraine aura: new cases, a literature review, and ideas about pathophysiology. Headache. 2014;54(8):1290–1309.
   PubMed Web of Science ®Google Scholar
• Schankin CJ, Viana M, Goadsby PJ. Persistent and repetitive visual disturbances in migraine: a review. Headache. 2017;57(1):1–16.
   PubMed Web of Science ®Google Scholar
• Joao AA, Goucha TB, Martins IP. Aura status: a not so frequent aura. Cephalalgia. 2014;34(14):1150–1162.
   PubMed Web of Science ®Google Scholar
• Belcastro V, Striano P, Verrotti A, et al. The growing landscape of ictal epileptic headache. Cephalalgia. 2018:333102418768077.
   PubMedGoogle Scholar
• Belcastro V, Striano P, Pierguidi L, et al. Ictal epileptic headache mimicking status migrainosus: EEG and DWI-MRI findings. Headache. 2011;51(1):160–162.
   PubMed Web of Science ®Google Scholar
• Perucca P, Terzaghi M, Manni R. Status epilepticus migrainosus: clinical, electrophysiologic, and imaging characteristics. Neurology. 2010;75(4):373–374.
   PubMed Web of Science ®Google Scholar
• Tang Y, Kang J, Zhang Y, et al. Influence of greater occipital nerve block on pain severity in migraine patients: a systematic review and meta-analysis. Am J Emerg Med. 2017;35(11):1750–1754.
   PubMed Web of Science ®Google Scholar
• Sacco S, Rasura M, Cao M, et al. CADASIL presenting as status migrainosus and persisting aura without infarction. J Headache Pain. 2009;10(1):51–53.
   PubMed Web of Science ®Google Scholar
• Martikainen MH, Roine S. Rapid improvement of a complex migrainous episode with sodium valproate in a patient with CADASIL. J Headache Pain. 2012;13(1):95–97.
   PubMed Web of Science ®Google Scholar
• Gunda B, Chabriat H, Bereczki D. [CADASIL and other hereditary small vessel diseases of the brain–increasingly diagnosed conditions underlying familial ischaemic stroke and dementia]. Ideggyogy Sz. 2011;64(3–4):88–100.
   PubMedGoogle Scholar